西隴科學(002584.SZ)第三季度淨利潤預增26.31%-60.76%
格隆匯10月14日丨西隴科學(002584.SZ)公佈,預計2021年前三季度歸屬於上市公司股東的淨利潤1.54億元-1.6億元,同比增長256.01%-269.88%;歸屬於上市公司股東的扣除非經常性損益的淨利潤4000萬元-4500萬元,上年同期為虧損190.03萬元;
其中,第三季度歸屬於上市公司股東的淨利潤2200萬元–2800萬元,同比增長26.31%-60.76%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1800萬元-2300萬元,上年同期為盈利1640.02萬元。
本期業績增長主要原因是轉讓控股子公司福建福君基因生物科技有限公司40.5%股權。
本期扣除非經常性損益後扭虧主要原因是本期信用減值損失較上期減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.